Laekna Limited
Clinical trials sponsored by Laekna Limited, explained in plain language.
-
New triple therapy aims to beat drug-resistant cancers
Disease control CompletedThis study tested a combination of three drugs (afuresertib, sintilimab, and chemotherapy) in 22 adults with solid tumors like lung, cervical, or stomach cancer that had stopped responding to prior immunotherapy. The goal was to find the safest dose and see if the combo could shr…
Phase: PHASE1, PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New hope for tough ovarian cancer: drug combo shows promise in clinical trial
Disease control CompletedThis study tested whether adding a new drug called afuresertib to standard chemotherapy (paclitaxel) helps control ovarian cancer that has stopped responding to platinum-based treatments. About 150 women with this hard-to-treat cancer took part. The goal was to see if the combina…
Phase: PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New drug LAE102 passes first safety check in healthy women
Knowledge-focused CompletedThis early-stage study tested a new drug called LAE102 in 32 healthy postmenopausal women to see if it is safe and how the body processes it. Participants received either a single dose of LAE102 or a placebo. The main goal was to check for side effects, not to treat any disease.
Phase: PHASE1 • Sponsor: Laekna Limited • Aim: Knowledge-focused
Last updated May 13, 2026 16:01 UTC